A Site-Specific MiniAp4-Trastuzumab Conjugate Prevents Brain Metastasis

Area of Science:

• Oncology
• Neuroscience
• Biotechnology

Background:

• Monoclonal antibodies (mAbs) show promise in cancer therapy but face challenges in penetrating the blood-brain barrier (BBB) and blood-tumor barrier (BTB).
• Brain shuttles, molecules that utilize endogenous transport systems, can enhance the delivery of large molecules across the BBB.
• Protease-resistant peptides like MiniAp-4 are efficient brain shuttles.

Purpose of the Study:

• To synthesize and evaluate antibody-brain shuttle conjugates (ASCs) for improved brain cancer treatment.
• To assess the efficacy of MiniAp-4 as a brain shuttle for the anti-HER2 monoclonal antibody trastuzumab (Tz).
• To determine if ASCs can overcome BBB/BTB limitations for central nervous system (CNS) disease treatment.

Main Methods:

• Site-specific conjugation of four MiniAp-4 molecules to the anti-HER2 mAb trastuzumab (Tz) to create antibody-brain shuttle conjugates (ASCs).
• Characterization of ASCs for binding affinity and functional capacity (cell cycle arrest).
• Evaluation of ASC transport across an in vitro BBB model and in a murine brain metastasis model.

Main Results:

• The synthesized ASCs retained the binding and therapeutic functions of trastuzumab.
• MiniAp-4 ASCs demonstrated superior transport across an in vitro BBB model compared to trastuzumab alone and trastuzumab conjugated to Angiopep-2.
• In vivo studies showed that Tz-MiniAp4 preferentially crossed the BBB/BTB, exerted a significant therapeutic effect, and protected against brain metastasis.

Conclusions:

• MiniAp-4 is an effective brain shuttle for enhancing monoclonal antibody delivery across the BBB/BTB.
• Antibody-brain shuttle conjugates offer a promising strategy for treating CNS diseases, including brain metastases.
• This technology has broad applicability for delivering therapeutic antibodies to the brain for various neurological conditions.